Intraoperative margin assessment during BCS using Perimeter B-Series OCT with ImgAssist AI 2.0 enabled surgeons to more effectively address residual cancer at the surgical margin as compared to current standard methods Primary endpoint met with statistically significant reduction in...Read more
PYX-201 achieved a confirmed 50% ORR by RECIST 1.1 including one Complete Response and 100% Disease Control Rate in six heavily pretreated HNSCC patients, supporting differentiated mono and front-line combo therapy expansion trials to begin dosing 1Q25 Overall, 26% ORR across all six...Read more
LOS ANGELES / Nov 20, 2024 / Business Wire / Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the initiation of its ALISertib in CAncer (ALISCA™-Breast1) Phase II trial (PUMA-ALI-1201; NCT06369285) of alisertib in combination with endocrine therapy for the...Read more
New Smart MDI system will be the first system to deliver real-time, personalized insights on when and how much to dose including for missed or inaccurate mealtime doses. GALWAY, Ireland, Nov. 20, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology,...Read more
Sangamo plans to initiate enrollment of patients in the Phase 1/2 study for ST-503 in mid-2025 RICHMOND, Calif. / Nov 19, 2024 / Business Wire / Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has cleared...Read more
The New Drug Application is based on positive results from the Phase 3 PALISADE study People living with familial chylomicronemia syndrome have extremely high triglyceride levels and a substantially higher risk of developing acute pancreatitis and associated long-term complications, including...Read more
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE| Company | Change | Last Trade |
|---|---|---|
| Eli Lilly | 23.68 3.25 | $753.41 |
| UnitedHealth | 23.50 4.07 | $600.50 |
| argenx | 17.28 3.01 | $591.82 |
| Humana | 16.19 5.83 | $293.97 |
| Alnylam Pharmaceuticals | 14.52 6.20 | $248.79 |
| Waters | 13.06 3.79 | $357.77 |
| Semler Scientific | 12.69 27.38 | $59.03 |
| Molina Healthcare | 12.14 4.30 | $294.64 |
| Medpace | 11.13 3.53 | $326.09 |
| Repligen | 10.41 8.10 | $138.90 |
| Finch Therapeutics | 9.65 536.11 | $11.45 |
| Inspire Medical Systems | 8.72 4.95 | $184.77 |
| Amgen | 8.13 2.90 | $288.08 |
| ICON | 8.07 4.13 | $203.67 |
| West Pharmaceutical | 7.56 2.49 | $311.66 |
| Forte Biosciences | 7.50 126.48 | $13.43 |
| Lantheus | 7.02 8.84 | $86.45 |
| BeiGene | 6.24 3.32 | $194.01 |
| Company | Volume | Last Trade |
|---|---|---|
| Tonix Pharmaceuticals | 654,513,644 | $0.19 |
| Quantum-Si | 278,845,174 | $1.38 |
| Pfizer | 44,158,947 | $24.92 |
| Vyome | 36,361,564 | $0.22 |
| Forte Biosciences | 29,378,859 | $13.43 |
| Eyenovia | 27,950,523 | $0.09 |
| Lineage Cell Therapeutics | 27,898,971 | $0.64 |
| Walgreens Boots Alliance | 24,873,335 | $8.21 |
| Exicure | 22,755,368 | $11.04 |
| Senseonics | 20,535,852 | $0.32 |
| Syros Pharmaceuticals | 16,804,532 | $0.28 |
| The Oncology Institute | 14,714,212 | $0.13 |
| Recursion | 14,375,750 | $6.04 |
| Aptevo Therapeutics | 12,599,179 | $0.29 |
| Seres Therapeutics | 12,189,542 | $0.83 |
| CVS Health | 11,060,119 | $56.83 |
| Bristol-Myers Squibb | 10,049,951 | $57.88 |
| Apollomics | 9,889,155 | $0.14 |
| Geron | 9,404,214 | $3.99 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
